HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis

Archives of Neurology

Volumn 66, Issue 12, 2009, Pages 1531-1536

  Sombekke, Madeleine H ^a   Lukas, Carsten ^a,b   Crusius, J Bart A ^a   Tejedor, Diego ^c   Killestein, Joep ^a   Arteta, David ^c   Martínez, Antonio ^c   Uitdehaag, Bernard M J ^a   Knol, Dirk L ^a   Peña, A Salvador ^a   Geurts, Jeroen J G ^a   De Jager, Philip L ^d   Barkhof, Frederik ^a   Vrenken, Hugo ^a   Polman, Chris H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ST JOSEF HOSPITAL   (Germany)

^c Progenika Biopharma SA   (Spain)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR ANTIGEN; HLA DRB1*1501, HUMAN; HLA-DRB1*1501, HUMAN;

ADULT; ALLELE; ARTICLE; BRAIN DAMAGE; CONGENITAL MALFORMATION; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPINAL CORD LESION; BRAIN; COMPARATIVE STUDY; GENETIC ASSOCIATION; GENETICS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; SPINAL CORD;

ADULT; BRAIN; FEMALE; GENETIC ASSOCIATION STUDIES; HLA-DR ANTIGENS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; SPINAL CORD;

EID: 73549090822     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.278     Document Type: Article

References (41)

1. Barcellos LF, Oksenberg JR, Begovich AB, et al; Multiple Sclerosis Genetics Group. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet. 2003;72(3):710-716.
2. Hoffmann S, Cepok S, Grummel V, et al. HLA-DRB1*0401 and HLA-DRB1* 0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis [published correction appears in Am J Hum Genet. 2008;83(4):541]. Am J Hum Genet. 2008;83(2):219-227.
3. Yamasaki K, Horiuchi I, Minohara M, et al. HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain. 1999;122(pt 9):1689-1696.
4. DeLuca GC, Ramagopalan SV, Herrera BM, et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci U S A. 2007;104(52):20896-20901.
5. Kantarci OH, de Andrade M, Weinshenker BG. Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol. 2002;123(1-2):144-159.
6. Barcellos LF, Sawcer S, Ramsay PP, et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet. 2006;15(18):2813-2824.
7. Fazekas F, Enzinger C, Ropele S, Schmidt H, Schmidt R, Strasser-Fuchs S. The impact of our genes: consequences of the apolipoprotein E polymorphism in Alzheimer disease and multiple sclerosis. J Neurol Sci. 2006;245(1-2):35-39.
8. van Veen T, van Winsen L, Crusius JB, et al. αB-crystallin genotype has impact on the multiple sclerosis phenotype. Neurology. 2003;61(9):1245-1249.
9. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47(6):707-717.
10. Lee MA, Smith S, Palace J, et al. Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? Brain. 1999;122(pt 7):1261-1270.
11. Nijeholt GJ, Bergers E, Kamphorst W, et al. Post-mortem high-resolution MRI of the spinal cord in multiple sclerosis: a correlative study with conventional MRI, histopathology and clinical phenotype. Brain. 2001;124(pt 1):154-166.
12. Bakshi R, Thompson AJ, Rocca MA, et al. MRI in multiple sclerosis: current status and future prospects. Lancet Neurol. 2008;7(7):615-625.
13. Fukazawa T, Yamasaki K, Ito H, et al. Both the HLA-DPB1 and -DRB1 alleles correlate with risk for multiple sclerosis in Japanese: clinical phenotypes and gender as important factors. Tissue Antigens. 2000;55(3):199-205.
14. Fukazawa T, Kikuchi S, Miyagishi R, et al. HLA- DPB1*0501 is not uniquely associated with opticospinal multiple sclerosis in Japanese patients: important role of DPB1*0301. Mult Scler. 2006;12(1):19-23.
15. Shibasaki H, McDonald WI, Kuroiwa Y. Racial modification of clinical picture of multiple sclerosis: comparison between British and Japanese patients. J Neurol Sci. 1981;49(2):253-271.
16. Matsuoka T, Matsushita T, Osoegawa M, et al. Association of the HLA-DRB1 alleles with characteristic MRI features of Asian multiple sclerosis. Mult Scler. 2008;14(9):1181-1190.
17. Deen S, Bacchetti P, High A, Waubant E. Predictors of the location of multiple sclerosis relapse. J Neurol Neurosurg Psychiatry. 2008;79(10):1190-1193.
18. Barcellos LF, Oksenberg JR, Green AJ, et al; Multiple Sclerosis Genetics Group. Genetic basis for clinical expression in multiple sclerosis. Brain. 2002;125(pt 1):150-158.
19. Butterfield RJ, Blankenhorn EP, Roper RJ, Zachary JF, Doerge RW, Teuscher C. Identification of genetic loci controlling the characteristics and severity of brain and spinal cord lesions in experimental allergic encephalomyelitis. Am J Pathol. 2000;157(2):637-645.
20. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227-231.
21. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria." Ann Neurol. 2005;58(6):840-846.
22. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33(11):1444- 1452.
23. Cutter GR, Baier ML, Rudick RA, et al. Development of multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122(pt 5):871-882.
24. Tejedor D, Castillo S, Mozas P, et al; Spanish FH Group. Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem. 2005;51(7):1137-1144.
25. van Walderveen MA, Barkhof F, Hommes OR, et al. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology. 1995;45(9):1684-1690.
26. Bot JC, Barkhof F, Polman CH, et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology. 2004;62(2):226-233.
27. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289-300.
28. de Bakker PI, McVean G, Sabeti PC, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet. 2006;38(10):1166-1172.
29. Hafler DA, Compston A, Sawcer S, et al; International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357(9):851-862.
30. Haines JL, Ter-Minassian M, Bazyk A, et al; Multiple Sclerosis Genetics Group. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. Nat Genet. 1996;13(4):469-471.
31. Zivadinov R, Uxa L, Zacchi T, et al. HLA genotypes and disease severity assessed by magnetic resonance imaging findings in patients with multiple sclerosis. J Neurol. 2003;250(9):1099-1106.
32. Honig LS, Sheremata WA. Magnetic resonance imaging of spinal cord lesions in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1989;52(4):459-466.
33. Lycklama à Nijeholt GJ, Barkhof F, Scheltens P, et al. MR of the spinal cord in multiple sclerosis: relation to clinical subtype and disability. AJNR AmJ Neuroradiol. 1997;18(6):1041-1048.
34. Furby J, Hayton T, Anderson V, et al. Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis. Mult Scler. 2008;14(8):1068-1075.
35. Okuda DT, Srinivasan R, Oksenberg JR, et al. Genotype-phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain. 2009;132(pt 1):250-259.
36. van Veen T, Nielsen J, Berkhof J, et al. CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. J Neuroimmunol. 2007;190(1-2):157-164.
37. Zivadinov R, Uxa L, Bratina A, et al. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. Int Rev Neurobiol. 2007;79:521-535.
38. Sepulcre J, Masdeu JC, Palacios R, et al. HLA-DR2 and white matter lesion distribution in MS. J Neuroimaging. 2008;18(3):328-331.
39. Fernando MM, Stevens CR, Walsh EC, et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet. 2008;4(4):e1000024.
40. Storch MK, Stefferl A, Brehm U, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol. 1998;8(4):681-694.
41. H17 cells. Nat Med. 2008;14(3):337-342.